Pages

▼
Friday, March 30, 2012

New Antibody Data Indicate Tough Battle for RNAi Therapeutic PCSK9 Approach

›
The past week has been a busy one for the hypercholesterolemia field. New clinical data for PCSK9-targeting monoclonal antibodies from Amge...
4 comments:
Wednesday, March 21, 2012

Fate of Quark Wet AMD Program in Limbo

›
PF-4523655 is arguably RNAi's most advanced clinical candidate. A naked, 19bp blunt-ended intravitreally injected AtuRNAi molecule, it ...
1 comment:
Friday, March 16, 2012

Alnylam Launches Pair of Pre-emptive PR Strikes to Cover Patent Losses

›
When the therapeutic relevance of a patent (Tuschl-I) that once had the potential to be broadly applicable to RNAi Therapeutics has been los...
12 comments:
Friday, March 9, 2012

Silence Strongly Disagrees with Alnylam’s Version of Tuschl I Hearing

›
On February 29, there was a hearing on the Tuschl I patent in Europe (EP 1309726; co-owners: UMass, MIT, Max-Planck, the Whitehead; license...
3 comments:
Thursday, March 8, 2012

Technology Trends: MicroRNA Inhibitors and Single-Strand RNAi

›
There have been developments in the areas of microRNA inhibition and single-strand RNA-mediated RNAi that might have strategic implications ...
8 comments:
Monday, March 5, 2012

RNAi Therapeutics Investors Are Getting More Selective

›
The recent share price performances of RNAi Therapeutics companies have confirmed that clinical data have become the critical new bar for in...
15 comments:
Sunday, March 4, 2012

Tekmira’s Drug Candidate for Alcohol Dependence Turns Intravenous Delivery into Strength

›
Tekmira’s SNALP delivery platform which makes up the majority of the active systemic RNAi Therapeutics pipeline symbolizes the potential eff...